# Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration

> **NCT04270669** · PHASE1,PHASE2 · COMPLETED · sponsor: **RemeGen Co., Ltd.** · enrollment: 37 (actual)

## Conditions studied

- Wet Age-Related Macular Degeneration

## Interventions

- **BIOLOGICAL:** intravitreal injection of RC28-E 0.5mg
- **BIOLOGICAL:** intravitreal injection of RC28-E 1.0mg
- **BIOLOGICAL:** intravitreal injection of RC28-E2.0mg

## Key facts

- **NCT ID:** NCT04270669
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-15
- **Primary completion:** 2021-10-29
- **Final completion:** 2021-10-29
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2022-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04270669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04270669, "Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04270669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*